It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Iron deposition is present in main lesion areas in the brains of patients with Parkinson’s disease (PD) and an abnormal iron content may be associated with dopaminergic neuronal cytotoxicity and degeneration in the substantia nigra of the midbrain. However, the cause of iron deposition and its role in the pathological process of PD are unclear. In the present study, we investigated the effects of the nasal mucosal delivery of synthetic human α-synuclein (α-syn) preformed fibrils (PFFs) on the pathogenesis of PD in Macaca fascicularis. We detected that iron deposition was clearly increased in a time-dependent manner from 1 to 17 months in the substantia nigra and globus pallidus, highly contrasting to other brain regions after treatments with α-syn PFFs. At the cellular level, the iron deposits were specifically localized in microglia but not in dopaminergic neurons, nor in other types of glial cells in the substantia nigra, whereas the expression of transferrin (TF), TF receptor 1 (TFR1), TF receptor 2 (TFR2), and ferroportin (FPn) was increased in dopaminergic neurons. Furthermore, no clear dopaminergic neuron loss was observed in the substantia nigra, but with decreased immunoreactivity of tyrosine hydroxylase (TH) and appearance of axonal swelling in the putamen. The brain region-enriched and cell-type-dependent iron localizations indicate that the intranasal α-syn PFFs treatment-induced iron depositions in microglia in the substantia nigra may appear as an early cellular response that may initiate neuroinflammation in the dopaminergic system before cell death occurs. Our data suggest that the inhibition of iron deposition may be a potential approach for the early prevention and treatment of PD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Institute of Neuroscience, College of Life and Health Sciences, Northeastern University, Shenyang, China (GRID:grid.412252.2) (ISNI:0000 0004 0368 6968)
2 Xuanwu Hospital of Capital Medical University, Beijing Key Laboratory of Parkinson’s Disease, National Clinical Research Center for Geriatric Disorders, Department of Neurobiology, Beijing, China (GRID:grid.413259.8) (ISNI:0000 0004 0632 3337)
3 CNRS and Institut François Jacob (MIRCen), CEA, Laboratory of Neurodegenerative Diseases, Fontenay-aux-Roses, France (GRID:grid.457349.8)
4 Chongqing Medical University, Department of Histology, Chongqing, China (GRID:grid.203458.8) (ISNI:0000 0000 8653 0555)
5 Unit of Neurodegenerative Diseases and Repair, Institute of Health Sciences, China Medical University, Shenyang, China (GRID:grid.412449.e) (ISNI:0000 0000 9678 1884)
6 Unit of Neurodegenerative Diseases and Repair, Institute of Health Sciences, China Medical University, Shenyang, China (GRID:grid.412449.e) (ISNI:0000 0000 9678 1884); Lund University, Neural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
7 Institute of Neuroscience, College of Life and Health Sciences, Northeastern University, Shenyang, China (GRID:grid.412252.2) (ISNI:0000 0004 0368 6968); Unit of Neurodegenerative Diseases and Repair, Institute of Health Sciences, China Medical University, Shenyang, China (GRID:grid.412449.e) (ISNI:0000 0000 9678 1884); Lund University, Neural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)




